Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?
Identifieur interne : 000032 ( Main/Exploration ); précédent : 000031; suivant : 000033Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?
Auteurs : Yesim Oymak ; Tuba H. Karapinar ; Lker Devrim [Turquie]Source :
- Journal of pediatric hematology/oncology [ 1536-3678 ] ; 2021.
Descripteurs français
- KwdFr :
- Déficit en glucose-6-phosphate-déshydrogénase (complications), Déficit en glucose-6-phosphate-déshydrogénase (diagnostic), Humains (MeSH), Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (usage thérapeutique), Hémolyse (effets des médicaments et des substances chimiques).
- MESH :
- administration et posologie : Hydroxychloroquine.
- diagnostic : Déficit en glucose-6-phosphate-déshydrogénase.
- effets des médicaments et des substances chimiques : Hémolyse.
- effets indésirables : Déficit en glucose-6-phosphate-déshydrogénase, Hydroxychloroquine.
- usage thérapeutique : Hydroxychloroquine.
- Humains.
English descriptors
- KwdEn :
- COVID-19 (complications), COVID-19 (drug therapy), Glucosephosphate Dehydrogenase Deficiency (complications), Glucosephosphate Dehydrogenase Deficiency (diagnosis), Hemolysis (drug effects), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use).
- MESH :
- chemical , administration & dosage : Hydroxychloroquine.
- chemical , adverse effects : Hydroxychloroquine.
- complications : COVID-19, Glucosephosphate Dehydrogenase Deficiency.
- diagnosis : Glucosephosphate Dehydrogenase Deficiency.
- drug effects : Hemolysis.
- drug therapy : COVID-19.
- chemical , therapeutic use : Hydroxychloroquine.
- Humans.
DOI: 10.1097/MPH.0000000000001864
PubMed: 32496442
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?</title><author><name sortKey="Oymak, Yesim" sort="Oymak, Yesim" uniqKey="Oymak Y" first="Yesim" last="Oymak">Yesim Oymak</name><affiliation><nlm:affiliation>Departments of Pediatric Hematology and Oncology.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatric Hematology and Oncology.</wicri:noCountry><wicri:noCountry code="no comma">Departments of Pediatric Hematology and Oncology.</wicri:noCountry></affiliation></author><author><name sortKey="Karapinar, Tuba H" sort="Karapinar, Tuba H" uniqKey="Karapinar T" first="Tuba H" last="Karapinar">Tuba H. Karapinar</name><affiliation><nlm:affiliation>Departments of Pediatric Hematology and Oncology.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatric Hematology and Oncology.</wicri:noCountry><wicri:noCountry code="no comma">Departments of Pediatric Hematology and Oncology.</wicri:noCountry></affiliation></author><author><name sortKey="Devrim, Lker" sort="Devrim, Lker" uniqKey="Devrim " first=" Lker" last="Devrim"> Lker Devrim</name><affiliation wicri:level="1"><nlm:affiliation>Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir</wicri:regionArea><wicri:noRegion>İzmir</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32496442</idno><idno type="pmid">32496442</idno><idno type="doi">10.1097/MPH.0000000000001864</idno><idno type="wicri:Area/Main/Corpus">001501</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001501</idno><idno type="wicri:Area/Main/Curation">001501</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001501</idno><idno type="wicri:Area/Main/Exploration">001501</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?</title><author><name sortKey="Oymak, Yesim" sort="Oymak, Yesim" uniqKey="Oymak Y" first="Yesim" last="Oymak">Yesim Oymak</name><affiliation><nlm:affiliation>Departments of Pediatric Hematology and Oncology.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatric Hematology and Oncology.</wicri:noCountry><wicri:noCountry code="no comma">Departments of Pediatric Hematology and Oncology.</wicri:noCountry></affiliation></author><author><name sortKey="Karapinar, Tuba H" sort="Karapinar, Tuba H" uniqKey="Karapinar T" first="Tuba H" last="Karapinar">Tuba H. Karapinar</name><affiliation><nlm:affiliation>Departments of Pediatric Hematology and Oncology.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatric Hematology and Oncology.</wicri:noCountry><wicri:noCountry code="no comma">Departments of Pediatric Hematology and Oncology.</wicri:noCountry></affiliation></author><author><name sortKey="Devrim, Lker" sort="Devrim, Lker" uniqKey="Devrim " first=" Lker" last="Devrim"> Lker Devrim</name><affiliation wicri:level="1"><nlm:affiliation>Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir</wicri:regionArea><wicri:noRegion>İzmir</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of pediatric hematology/oncology</title><idno type="eISSN">1536-3678</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (complications)</term><term>COVID-19 (drug therapy)</term><term>Glucosephosphate Dehydrogenase Deficiency (complications)</term><term>Glucosephosphate Dehydrogenase Deficiency (diagnosis)</term><term>Hemolysis (drug effects)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Déficit en glucose-6-phosphate-déshydrogénase (complications)</term><term>Déficit en glucose-6-phosphate-déshydrogénase (diagnostic)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (administration et posologie)</term><term>Hydroxychloroquine (effets indésirables)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Hémolyse (effets des médicaments et des substances chimiques)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term><term>Glucosephosphate Dehydrogenase Deficiency</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Glucosephosphate Dehydrogenase Deficiency</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Déficit en glucose-6-phosphate-déshydrogénase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hemolysis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Hémolyse</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Déficit en glucose-6-phosphate-déshydrogénase</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32496442</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-3678</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>01</Month></PubDate></JournalIssue><Title>Journal of pediatric hematology/oncology</Title><ISOAbbreviation>J Pediatr Hematol Oncol</ISOAbbreviation></Journal><ArticleTitle>Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?</ArticleTitle><Pagination><MedlinePgn>35-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MPH.0000000000001864</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oymak</LastName><ForeName>Yesim</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Departments of Pediatric Hematology and Oncology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karapinar</LastName><ForeName>Tuba H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Departments of Pediatric Hematology and Oncology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devrim</LastName><ForeName>İlker</ForeName><Initials>İ</Initials><AffiliationInfo><Affiliation>Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pediatr Hematol Oncol</MedlineTA><NlmUniqueID>9505928</NlmUniqueID><ISSNLinking>1077-4114</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005955" MajorTopicYN="N">Glucosephosphate Dehydrogenase Deficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006461" MajorTopicYN="N">Hemolysis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32496442</ArticleId><ArticleId IdType="doi">10.1097/MPH.0000000000001864</ArticleId><ArticleId IdType="pii">00043426-202101000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207.</Citation></Reference><Reference><Citation>World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19—March 11, 2020. Available at: www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed April 25, 2020.</Citation></Reference><Reference><Citation>Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.</Citation></Reference><Reference><Citation>Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72–73.</Citation></Reference><Reference><Citation>Colson P, Rolain J-M, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55:105923.</Citation></Reference><Reference><Citation>Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;9:ciaa237.</Citation></Reference><Reference><Citation>Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.</Citation></Reference><Reference><Citation>Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271.</Citation></Reference><Reference><Citation>Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020. Doi:10.1056/NEJMoa2012410.</Citation></Reference><Reference><Citation>FDA. Hydroxychloroquine or chloroquine for COVID-19: drug safety communication—FDA cautions against use outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Available at: www.fda.gov/safety/medical-product-safety-information/hydroxychloroquine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use. Accessed April 25, 2020.</Citation></Reference><Reference><Citation>Beauverd Y, Adam Y, Assouline B, et al. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. Eur J Haematol. 2020. Doi: 10.1111/ejh.13432.</Citation></Reference><Reference><Citation>FDA Safety Alert. MedWatch. Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. Available at: www.fda.gov/media/136537/download. Accessed April 1, 2020.</Citation></Reference><Reference><Citation>Krzelj V, Zlodre S, Terzic J, et al. Prevalence of G-6-PD deficiency in the Croatian Adriatic coast population. Arch Med Res. 2001;32:454–457.</Citation></Reference><Reference><Citation>Missiou T, Sagaraki S. Screening for glucose 6-phosphate dehydroge- nase deficiency as a preventive measure: prevalence among 1,286,000 Greek newborn infants. J Pediatr. 1991;119:293–299.</Citation></Reference><Reference><Citation>Martinez Di Montemuros F, Dotti C, Tavazzi D, et al. Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in Italy. Haematologica. 1997;82:440–445.</Citation></Reference><Reference><Citation>Luzzatto L, Mehta AScriver CR. Glucose-6-phosphate dehydrogenase deficiency. The Metabolic and Molecular Bases of Inherited Diseases, 7th ed. New York, NY: Harper Row; 1995:3367–3398.</Citation></Reference><Reference><Citation>Gelpi AP, King MC. New data on glucose-6-phosphate dehydrogenase deficiency in Saudi Arabia. G6PD variants, and the association between enzyme deficiency and hemoglobins. Hum Hered. 1977;27:285–291.</Citation></Reference><Reference><Citation>G6PD deficiency favism association website. Available at: www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare_ISS-it.</Citation></Reference><Reference><Citation>Mohammad S, Clowse MEB, Eudy AM, et al. Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients. Arthritis Care Res (Hoboken). 2018;70:481–485.</Citation></Reference><Reference><Citation>Grobusch MP, Rodríguez-Morales AJ, Schlagenhauf P. The primaquine problem-and the solution? Point-of-care diagnostics for glucose 6-phosphate dehydrogenase deficiency. Clin Infect Dis. 2019;69:1443–1445.</Citation></Reference><Reference><Citation>Baird JK. Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency. BMC Med. 2015;13:296.</Citation></Reference><Reference><Citation>Bhutani VK, Kaplan M, Glader B, et al. Point-of-care quantitative measure of glucose-6-phosphate dehydrogenase enzyme deficiency. Pediatrics. 2015;136:e1268–e1275.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Turquie</li></country></list><tree><noCountry><name sortKey="Karapinar, Tuba H" sort="Karapinar, Tuba H" uniqKey="Karapinar T" first="Tuba H" last="Karapinar">Tuba H. Karapinar</name><name sortKey="Oymak, Yesim" sort="Oymak, Yesim" uniqKey="Oymak Y" first="Yesim" last="Oymak">Yesim Oymak</name></noCountry><country name="Turquie"><noRegion><name sortKey="Devrim, Lker" sort="Devrim, Lker" uniqKey="Devrim " first=" Lker" last="Devrim"> Lker Devrim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000032 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000032 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32496442
|texte= Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32496442" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |